Vectus Biosystems (ASX:VBS)
We spoke with Dr Karen Duggan, CEO of drug developer Vectus Biosystems (ASX:VBS), about the potential of her company to develop an effective anti-fibrosis drug. We also spoke about Vectus’s phase 1b clinical trial for VB0004, which targets the prevention and reversal of fibrosis in the heart and kidneys. Vectus has an interesting pipeline that includes VB4-A32 (for the treatment of liver fibrosis), VB4-A79 (for pulmonary fibrosis, including asbestosis and coal dust pneumoconiosis or black lung disease) and VB4-P5 (renal tubular cell death from chemotherapies).
Have you signed up for our weekly Investor Newsletter yet?
The best of Stocks Down Under in your inbox every Saturday morning!
SIGN UP FOR THE STOCKS DOWN UNDER NEWSLETTER NOW!
